OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Huang Discusses Robotic Surgery for Bladder Cancer

January 27th 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses robotic surgery in the treatment of bladder cancer.

Dr. Wysock on Robotic Approaches in Cytoreductive Nephrectomy

January 27th 2018

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the placement of novel robotic and minimally invasive approaches in nephrectomy.

Dr. Wong on the Difficulty of Diagnosing Patients With AL Amyloidosis

January 27th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses the presentation of AL amyloidosis in patients.

Dr. Locke on the ZUMA-6 Trial of Axi-Cel With Atezolizumab for DLBCL

January 26th 2018

Frederick Locke, MD, Moffitt Cancer Center, discusses the results of the ZUMA-6 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab (Tecentriq) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).

Differentiating Molecular Risk Assessments of Prostate Cancer

January 26th 2018

Marc A. Bjurlin, DO, clinical assistant professor, Department of Urology, NYU Langone Medical Center, discusses differentiating molecular risk assessments for patients with prostate cancer.

Dr. Janjigian on Immunotherapy in Esophageal and Gastric Cancer

January 26th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with gastric and esophageal cancer.

Dr. Strosberg on FDA Approval of Lutathera for GEP-NETs

January 26th 2018

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the FDA approval of Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Isaacs Discusses the Role of Neratinib in HER2+ Breast Cancer

January 26th 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the role of neratinib (Nerlynx) in the treatment landscape of HER2-positive breast cancer.

Dr. Bauml Discusses Liquid Biopsies in Lung Cancer

January 26th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Dr. Barrientos on the Role of Acalabrutinib in CLL

January 26th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Dr. Singh Discusses Immunotherapy Study in GIST

January 26th 2018

Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

Dr. Zhang Discusses Neoadjuvant Therapy in Kidney Cancer

January 25th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

Dr. Califano Discusses the Role of Surgery in Head and Neck Cancer

January 25th 2018

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of surgery in head and neck cancer.

Dr. Coit on the Evolving Role of Surgery in Patients With Melanoma

January 25th 2018

Daniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

January 25th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the results of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Dr. Brentjens Discusses Potential for CAR T-Cell Therapy in Solid Tumors

January 25th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential for chimeric antigen receptor therapy (CAR) T-cell therapy in solid tumors.

Dr. Bosch Discusses the Importance of the HPV Vaccine

January 25th 2018

Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, discusses the importance of the HPV vaccine in the prevention of cervical cancer.

Dr. O'Connor on Treatment Options Following Ibrutinib Progression in MCL

January 25th 2018

Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses treatment options following progression on ibrutinib (Imbruvica) for patients with mantle cell lymphoma (MCL).

Dr. Sonpavde on Ongoing Trials With Immunotherapy for Penile Cancer

January 25th 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses ongoing trials investigating immunotherapy for patients with penile cancer.

Dr. Davids on Results of Obinutuzumab With Ibrutinib in CLL

January 25th 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia (CLL), discusses the initial results of a phase Ib study of ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with relapsed or refractory CLL.